U.S. markets closed

FUJIFILM Holdings Corporation (FUJIY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
61.35+0.94 (+1.56%)
At close: 3:50PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close60.41
Open61.94
Bid0.00 x 0
Ask0.00 x 0
Day's Range60.72 - 61.94
52 Week Range42.11 - 63.09
Volume6,445
Avg. Volume12,124
Market Cap24.578B
Beta (5Y Monthly)0.17
PE Ratio (TTM)20.63
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.91 (1.48%)
Ex-Dividend DateSep 28, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Fujifilm CEO Komori, who oversaw push into healthcare, to step down in June
    Reuters

    Fujifilm CEO Komori, who oversaw push into healthcare, to step down in June

    Fujifilm Holdings Corp said on Wednesday that Shigetaka Komori, who oversaw the company's transition from film business to healthcare, would step down as chairman and chief executive in June. Komori, 81, will take a new role as chief adviser while Teiichi Goto becomes CEO and Kenji Sukeno the chairman. The transitions are subject to approval by shareholders, Fujifilm said in a release.

  • Is Fujifilm Holdings Corp. (FUJIY) Stock Undervalued Right Now?
    Zacks

    Is Fujifilm Holdings Corp. (FUJIY) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Fujifilm's Avigan shows no significant benefit on COVID-19 mortality - study
    Reuters

    Fujifilm's Avigan shows no significant benefit on COVID-19 mortality - study

    A study of global trials of Fujifilm Holdings Corp's antiviral drug Avigan suggests it has little benefit for COVID-19 patients once their symptoms become serious. The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalisation, according to the preprint of a study posted Wednesday on the medical website medRxiv. "We should consider that perhaps the use of antivirals once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting," wrote the authors, led by Soheil Hassanipoura of Iran's Guilan University of Medical Sciences.